Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.06. | Abivax Announces Results of its June 6, 2025 Annual General Meeting | 425 | Dow Jones News | DJ Abivax Announces Results of its June 6, 2025 Annual General Meeting
ABIVAX
Abivax Announces Results of its June 6, 2025 Annual General Meeting
11-Jun-2025 / 22:00 CET/CEST
Dissemination of... ► Artikel lesen | |
11.06. | EQS-News: ABIVAX: Abivax Announces Results of its June 6, 2025 Annual General Meeting | 334 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its June 6, 2025 Annual General Meeting
11.06.2025 / 22:00 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
11.06. | Abivax S.A. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
03.06. | Abivax: Höherer Nettoverlust, Cash-Reserve schrumpft schnell | 664 | 4investors | Abivax hat im ersten Quartal 2025 einen Nettoverlust von 52,4 Millionen Euro ausgewiesen, verglichen mit 42,9 Millionen Euro im Vorjahreszeitraum. Der Anstieg resultiert nach Angaben des französischen... ► Artikel lesen | |
02.06. | Abivax reports Q1 results | 16 | Seeking Alpha | ||
02.06. | Abivax S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
ABIVAX SA ADR Aktie jetzt für 0€ handeln | |||||
02.06. | EQS-News: ABIVAX: Abivax Presents First Quarter 2025 Financial Results | 362 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Quarter Results
Abivax Presents First Quarter 2025 Financial Results
02.06.2025 / 22:00 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
30.04. | JMP maintains $33 target on Abivax stock amid Phase 3 progress | 48 | Investing.com | ||
29.04. | EQS-News: ABIVAX: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis | 423 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Study
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis... ► Artikel lesen | |
22.04. | Abivax S.A. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
22.04. | Abivax beruft Immunologie-Experten in den Vorstand vor Studienergebnissen | 10 | Investing.com Deutsch | ||
22.04. | Abivax adds immunology expert to board ahead of trial results | 2 | Investing.com | ||
22.04. | EQS-News: ABIVAX: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones | 520 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
22.04.2025 / 22:05... ► Artikel lesen | |
22.04. | EQS-News: ABIVAX: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors | 432 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
22.04.2025 / 22:00 CET/CEST
The issuer is solely... ► Artikel lesen | |
26.03. | EQS-News: ABIVAX: Abivax publishes financial reports with the French and U.S. securities regulatory agencies | 431 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Annual Report
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
26.03.2025 / 22:05 CET/CEST
The... ► Artikel lesen | |
25.03. | BTIG maintains $43 target on Abivax stock following analyst event | 36 | Investing.com | ||
24.03. | Abivax S.A. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
24.03. | Abivax S.A. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
24.03. | Abivax reports FY results | 3 | Seeking Alpha | ||
24.03. | Abivax meldet Zahlen für 2024 - Cash reicht bis Q4 2025 | 628 | 4investors | Abivax hat im Geschäftsjahr 2024 einen Nettoverlust von 176,2 Millionen Euro ausgewiesen, nach 147,8 Millionen Euro im Vorjahr. Der operative Fehlbetrag stieg auf 172,9 Millionen Euro, was vor allem... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |